尿道血管素分泌量升高与中央和脏血动力学变化有关
Keisei Kosaki1,2, Jiyeon Park3, Masahiro Matsui3
1Institute of Health and Sport Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8574, Japan. kosaki.keisei.gm@u.tsukuba.ac.jp.
Scientific reports
|July 17, 2023
概括
尿液中的血管激素 (AGT) 水平与成人血压和脏血流有关. 较高的AGT表明心综合征 (CRS) 的风险更高,突出显示了内氨基酶系统 (RAS) 的活性.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學.
- 脏生理学 脏生理学
背景情况:
- 内-血管素系统 (RAS) 在心综合征 (CRS) 发病过程中发挥作用.
- 尿道中的血管增生素 (AGT) 排泄作为内RAS活性的生物标志物.
研究的目的:
- 为了研究尿液AGT水平和中年和老年人血液动力学参数之间的关联.
- 探索内RAS活性与中央/内血动力学之间的关系,特别是在慢性病 (CKD) 患者中.
主要方法:
- 这是一项涉及282名参与者的横截面研究.
- 测量大动脉和脏的血液动力学参数,使用平面化度和双重超声波.
- 测定尿中的AGT,肝型脂肪酸结合蛋白 (L-FABP) 和血N终端B型亲尿素 (NT-proBNP).
主要成果:
- 尿中的AGT水平与大动脉血压和脏血流相关.
- 在对年龄,性别,BMI,GFR和药物等共变量进行调整后,关联仍然存在.
- 在具有较低GFR和更高尿路AGT的参与者中观察到较高的NT-proBNP和L-FABP水平.
结论:
- 尿液中的AGT分泌是中年和老年人中枢和脏血液动力学的重要决定因素.
- 这些发现支持内RAS活性在CRS发展中的作用.
- 尿液AGT可以作为评估CRS风险的有价值的临床标志物.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
696
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
696
Antihypertensive Drugs: Direct Renin Inhibitors
697
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
697
Hypertension II: Pathophysiology
20
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
20
Hormonal Regulation
33.4K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.4K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
786
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
786
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465


